Search Results

Naturally Occurring Compounds as Potential Inhibitors of Epidermal Growth Factor Receptors (EGFRs).

• Authors : Oktavia L; Department of Chemistry, Research Center for Pharmaceutical Ingredient and Traditional Medicine, National Research and Innovation Agency (BRIN), Cibinong, Bogor, Jawa Barat, 16911, Indonesia.; Fuad AM

Subjects: Neoplasms*/Neoplasms*/Neoplasms*/drug therapy ; Biological Products*/Biological Products*/Biological Products*/pharmacology ; Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/pharmacology

• Source: Combinatorial chemistry & high throughput screening [Comb Chem High Throughput Screen] 2023; Vol. 26 (6), pp. 1093-1107.Publisher: Bentham Science Publishers Country of Publication: United Arab Emirates NLM ID: 9810948 Publication Model: Print Cited Medium: Internet

Record details

Inoperable stage III EGFR mutant non-small-cell lung cancer: time for drug first, local later?

• Authors : John, A.¹ (AUTHOR); McDonald, F.^1,2 (AUTHOR); Popat, S.^1,2 (AUTHOR)

Subjects: *NON-small-cell lung carcinoma; *EPIDERMAL growth factor receptors; *ANTINEOPLASTIC agents

• Source: Annals of Oncology. Dec2024, Vol. 35 Issue 12, p1074-1076. 3p.

Record details

Applied Science & Technology Full Text (H.W. Wilson)

Record details

Applied Science & Technology Full Text (H.W. Wilson)

Record details

Highlights on Specific Biological Targets; Cyclin-Dependent Kinases, Epidermal Growth Factor Receptors, Ras Protein, and Cancer Stem Cells in Anticancer Drug Development.

• Authors : Hawash M; Department of Pharmacy, Faculty of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine.

Subjects: Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*pharmacology ; Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*therapeutic use ; Cyclin-Dependent Kinases/Cyclin-Dependent Kinases/Cyclin-Dependent Kinases/*metabolism

• Source: Drug research [Drug Res (Stuttg)] 2019 Sep; Vol. 69 (9), pp. 471-478. Date of Electronic Publication: 2019 May 13.Publisher: Thieme Country of Publication: Germany NLM ID: 101602406 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2194-9387

Record details

Click chemistry for improvement in selectivity of quinazoline-based kinase inhibitors for mutant epidermal growth factor receptors.

• Authors : Song J; College of Pharmacy, Chung-Ang University, Seoul 06974, Republic of Korea.; Jang S

Subjects: Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*pharmacology ; Protein Kinase Inhibitors/Protein Kinase Inhibitors/Protein Kinase Inhibitors/*pharmacology ; Quinazolines/Quinazolines/Quinazolines/*pharmacology

• Source: Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2019 Feb 01; Vol. 29 (3), pp. 477-480. Date of Electronic Publication: 2018 Dec 11.Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9107377 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Applied Science & Technology Full Text (H.W. Wilson)

Record details

Applied Science & Technology Full Text (H.W. Wilson)

Record details

First case report of erlotinib plus ramucirumab treatment for lung carcinosarcoma with EGFR L858R mutation.

• Authors : Ishibashi, Naoya¹ (AUTHOR) ; Tabata, Toshiharu¹ (AUTHOR); Nonomura, Ryo¹ (AUTHOR)

Subjects: *GENETIC mutation; *EPIDERMAL growth factor receptors; *ERLOTINIB

• Source: Thoracic Cancer. Dec2023, Vol. 14 Issue 34, p3415-3418. 4p.

Record details

597TiP A phase I/II study to evaluate the safety and anti-tumor activity of JIN-A02 in patients with EGFR TKI-refractory, EGFR-mutant advanced NSCLC.

• Authors : Lim, S.M.¹ (AUTHOR); Cho, B.C.² (AUTHOR); Han, J-Y.³ (AUTHOR)

Subjects: *ANTINEOPLASTIC agents; *EPIDERMAL growth factor receptors; *NON-small-cell lung carcinoma

• Source: Annals of Oncology. 2023 Supplement 4, Vol. 34, pS1704-S1705. 2p.

Record details